Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distance from low-density lipoprotein cholesterol targets across cardiovascular risk strata in people living with HIV: a multicentre cohort study.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Infectious Complications in Metabolic and Bariatric Surgery: A Comprehensive Narrative Review of Pathophysiology, Prevention, and Management.

Life (Basel, Switzerland)·2026
Same author

Genital Dirofilaria: A Comprehensive Review of Clinical Presentations, Diagnosis and Management.

Acta parasitologica·2026
Same author

Cognitive and fine motor performance in people above 65 years of age with and without HIV.

Scientific reports·2026
Same author

Ceftazidime-avibactam as monotherapy or in combination for targeted treatment of KPC-producing Klebsiella pneumoniae infections in ICUs: a comparative analysis through counterfactual framework and desirability of outcome ranking.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2026
Same author

Immune checkpoint landscape in CD4⁺ T cells stratifies HIV-infected individuals by clinical progression.

Immunologic research·2026

Related Experiment Video

Updated: May 20, 2026

Long Term Intravital Multiphoton Microscopy Imaging of Immune Cells in Healthy and Diseased Liver Using CXCR6.Gfp Reporter Mice
11:44

Long Term Intravital Multiphoton Microscopy Imaging of Immune Cells in Healthy and Diseased Liver Using CXCR6.Gfp Reporter Mice

Published on: March 24, 2015

Microbial translocation in chronic liver diseases.

Marilia Rita Pinzone1, Benedetto Maurizio Celesia, Michele Di Rosa

  • 1Division of Infectious Diseases, Department of Clinical and Molecular Biomedicine, University of Catania, 95125 Catania, Italy.

International Journal of Microbiology
|August 1, 2012
PubMed
Summary

Gut microflora derangement can cause microbial translocation (MT), impacting liver disease progression and complications. Probiotics show promise for reducing MT, but require larger clinical trials for confirmation.

More Related Videos

Laparoscopic Technique for Serial Collection of Liver and Mesenteric Lymph Nodes in Macaques
11:06

Laparoscopic Technique for Serial Collection of Liver and Mesenteric Lymph Nodes in Macaques

Published on: May 2, 2017

Related Experiment Videos

Last Updated: May 20, 2026

Long Term Intravital Multiphoton Microscopy Imaging of Immune Cells in Healthy and Diseased Liver Using CXCR6.Gfp Reporter Mice
11:44

Long Term Intravital Multiphoton Microscopy Imaging of Immune Cells in Healthy and Diseased Liver Using CXCR6.Gfp Reporter Mice

Published on: March 24, 2015

Laparoscopic Technique for Serial Collection of Liver and Mesenteric Lymph Nodes in Macaques
11:06

Laparoscopic Technique for Serial Collection of Liver and Mesenteric Lymph Nodes in Macaques

Published on: May 2, 2017

Area of Science:

  • Gastroenterology and Hepatology
  • Microbiology
  • Immunology

Background:

  • The intestinal microflora plays a crucial role in nutrient digestion and local immunity, acting as a barrier against pathogens.
  • Derangement of gut microflora can lead to microbial translocation (MT), the passage of microorganisms or bacterial products from the gut to extraintestinal sites.
  • MT is increasingly recognized in early-stage liver diseases like alcoholic and nonalcoholic fatty liver disease, not just cirrhosis.

Purpose of the Study:

  • To review the mechanisms and implications of microbial translocation in liver diseases.
  • To explore therapeutic strategies for modulating gut microflora and reducing MT.
  • To highlight the potential of probiotics as a therapeutic option.

Main Methods:

  • Literature review of mechanisms favoring MT (e.g., bacterial overgrowth, increased intestinal permeability, impaired immunity).
  • Analysis of MT's role in the pathogenesis of cirrhosis complications.
  • Evaluation of current and emerging therapeutic strategies, including antibiotics and probiotics.

Main Results:

  • Microbial translocation is implicated in the pathogenesis of liver disease complications, contributing to morbidity and mortality.
  • Mechanisms such as small intestinal bacterial overgrowth, increased intestinal permeability, and impaired immunity facilitate MT.
  • Antibiotic-based and non-antibiotic-based therapies are being explored to reduce MT.

Conclusions:

  • Microbial translocation is a significant factor in liver disease progression and complications.
  • Modulating the gut microflora and reducing MT are key therapeutic goals.
  • Probiotics represent a promising, though not yet fully validated, strategy for managing MT in liver disease.